The review’s central thesis is that mature ILC identity is not fixed at birth. Developmental programming establishes each cell’s lineage potential through an interconnected network of transcription factors, including NFIL3, TOX, TCF-1, GATA3, and the inhibitor Id2, which suppresses alternative B- and T-cell fates while supporting innate lymphoid commitment. Intermediate progenitors such as the common helper innate lymphoid progenitor, described by Klose and colleagues, generate helper-like ILC1s, ILC2s, ILC3s, and lymphoid tissue inducer cells while excluding conventional lymphocyte potential. For the type 2 compartment most relevant to allergy, murine genetic studies identify Bcl11b as essential for ILC2 development, and human experiments confirm that GATA3 is required for cytokine production by these cells.

Recent findings have complicated the traditional fetal-liver-to-bone-marrow developmental sequence. In the human embryo, Ni and colleagues identified yolk-sac-derived lymphoid-biased progenitors that appear before definitive hematopoietic stem cells, preferentially generating ILCs and dendritic cells. In mice, Wang and colleagues showed that fetal-liver-derived ILC progenitors seed developing organs, where local niches direct differentiation into tissue-associated precursors that can persist into adulthood and maintain local ILC pools independently of continuous bone-marrow output. The result is a layered model of ILC ontogeny in which embryonic, fetal, and adult sources contribute differently depending on developmental stage, tissue, and inflammatory context.

Once ILCs colonize barrier tissues, environmental education takes over. Parabiosis experiments demonstrated that ILCs in the lung, intestine, adipose tissue, and skin persist mainly through local self-renewal rather than continuous replacement from the circulation, allowing them to integrate information about epithelial integrity, stromal activity, vascular function, neuronal signaling, and microbial composition before mounting responses. Single-cell transcriptomics has reinforced this picture of tissue conditioning: ILC2s isolated from different organs retain a conserved lineage program while acquiring distinct tissue-specific signatures, and human datasets across blood, lymphoid tissue, mucosa, and tumors show both conserved features and strong tissue-specific imprinting. Spatial mapping by Van Acker and colleagues further revealed that ILC subsets occupy non-random positions within human lymphoid tissues, preferentially adjacent to functionally corresponding T-cell populations.

Perhaps the most striking dimension of ILC biology is plasticity. Human ILC2s exposed to IL-12 and IL-1β upregulate T-bet, gain responsiveness to IL-18, and produce interferon-γ while reducing canonical type 2 functions, effectively acquiring ILC1-like characteristics; IL-4 can reverse this shift in culture. Comparable flexibility exists within the ILC3 compartment, where inflammatory mediators promote ILC1-like conversion, while stabilizers such as the circadian nuclear receptors REV-ERBα and REV-ERBβ preserve intestinal ILC3 identity. The authors caution, however, that cytokine-driven conversion in culture demonstrates potential rather than clinical reality: claims of durable lineage conversion in human allergic tissue require longitudinal and perturbational evidence, not merely shifts in surface markers.

Under physiological conditions, ILCs perform remarkable housekeeping duties. ILC3s serve as central regulators of intestinal epithelial defense through IL-22, which can act directly on intestinal stem cells to support epithelial regeneration after injury. In the respiratory tract, lung-resident ILC2s accelerate recovery from influenza-induced epithelial damage through amphiregulin production, which signals via the epidermal growth factor receptor to support epithelial and stromal-cell survival and proliferation. In adipose tissue, ILC2-derived IL-5 and IL-13 sustain eosinophils and alternatively activated macrophages, contributing to an anti-inflammatory environment and even linking tissue immunity to thermogenesis and energy expenditure. The outcome of these pathways depends critically on magnitude, timing, and duration: transient mediator production supports repair, whereas persistent production drives goblet-cell metaplasia, fibroblast activation, extracellular matrix deposition, and remodeling.

ILCs also operate within multicellular niches that increasingly appear central to both health and disease. Fibroblasts, once viewed as passive matrix producers, actively organize ILC compartments: in the intestine, distinct fibroblastic reticular-cell populations support different ILC pools, and in experimental arthritis, Rauber and colleagues identified CD200-positive fibroblasts that interact with ILC2s to promote a pro-resolving tissue environment. Conversely, in experimental silicosis, mechanically activated fibroblasts redirect ILC phenotype through Notch3- and IL-18-dependent signaling, illustrating how stromal instruction can push ILCs toward pathology. Neuronal circuits add another layer: the neuropeptide neuromedin U, released by enteric and sensory neurons, potently activates ILC2s through its receptor, while sympathetic β2-adrenergic signaling restrains excessive type 2 responses, and vasoactive intestinal peptide links feeding behavior to intestinal ILC3 function.

The review’s most clinically consequential section addresses what happens when these homeostatic programs fail. In asthma, epithelial-derived IL-33, IL-25, and TSLP activate airway ILC2s, which produce IL-5 and IL-13 to drive eosinophilic inflammation and airway hyperresponsiveness. Christianson and colleagues showed that established allergic airway disease is maintained through interacting feedback circuits involving IL-33, ILC2s, and adaptive lymphocytes, while Verma and colleagues demonstrated that experimental asthma persists even in mice lacking the IL-33 receptor because TSLP-driven IL-9-positive and IL-13-positive ILC2 subpopulations emerge to sustain inflammation. This functional redundancy helps explain why blockade of single epithelial alarmins sometimes yields limited efficacy. Human studies confirm activated ILC2 accumulation in bronchoalveolar lavage fluid, sputum, and biopsies of eosinophilic asthma patients, with the greatest expansion in severe disease.

One of the most clinically significant findings involves corticosteroid resistance, a defining feature of severe asthma. Kabata and colleagues demonstrated that TSLP protects human ILC2s from glucocorticoid-mediated suppression through STAT5 signaling, and Liu and colleagues showed that in airway ILC2s from severe asthma patients, TSLP activates MEK and STAT5 pathways that restore cytokine production despite dexamethasone treatment; pharmacological inhibition of these pathways largely recovered steroid sensitivity. Subsequent work revealed that combined IL-33, TSLP, and IL-7 signaling activates JAK-STAT5-dependent expression of the anti-apoptotic molecule Bcl-xL alongside PI3K-Akt-mTOR pathways, keeping activated ILC2s alive during chronic inflammation. The reviewers also highlight newer regulators, including NFκB1, which restrains memory-like ILC2 responses, and the chromobox protein CBX7, whose genetic deletion or pharmacological inhibition markedly reduced cytokine production and suppressed allergic airway inflammation in multiple models.

Similar failed-homeostasis logic extends across allergic organs, though the authors are careful to note that each disease follows its own tissue-specific architecture. In chronic rhinosinusitis with nasal polyps, IL-33-responsive cells in nasal polyps produce IL-13, and ILC2s are enriched and activated in polyp tissue, although cross-sectional findings cannot establish causality. In eosinophilic esophagitis, Doherty and colleagues found expanded ILC2 populations correlating with tissue eosinophilia and disease activity, while recent single-cell atlases of active and remitting disease reveal dynamic rewiring across epithelial, stromal, myeloid, and lymphoid compartments. In atopic dermatitis, expanded cutaneous ILC2s respond to epithelial cytokines, and sensory neurons co-opt IL-4 and IL-13 signaling through neuronal IL-4Rα and Janus kinase pathways to mediate chronic itch, creating a self-reinforcing scratch-barrier injury cycle. Approved biologics targeting TSLP, IL-4Rα, IL-5, IL-13, and IgE demonstrate clinical benefit across these diseases, but because these pathways are shared by multiple cell types, clinical responses do not establish ILC2-specific efficacy. The reviewers argue that the next therapeutic frontier lies not in simply suppressing inflammation but in restoring tissue homeostasis itself, requiring longitudinal human studies, perturbable ex vivo systems, and matched animal models to identify which niche signals permit successful resolution and which stabilize the fibroblast activation and matrix deposition that make allergic disease chronic.

Subject of Research: Innate lymphoid cells as regulators of tissue homeostasis and their role in chronic allergic diseases

Article Title: Innate lymphoid cells as central regulators of tissue homeostasis: implications for allergic diseases

Article References: Sirohi, K., & Yadav, S. (2026). Innate lymphoid cells as central regulators of tissue homeostasis: implications for allergic diseases. Frontiers in Allergy, 7, Article 1954214. https://doi.org/10.3389/falgy.2026.1954214

Image Credits: AI Generated

DOI: 10.3389/falgy.2026.1954214

Keywords: innate lymphoid cells, ILC2, tissue homeostasis, allergic disease, asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis, epithelial alarmins, IL-33, TSLP, neuroimmune signaling

The researchers, led by Mami Amaki and Yasutomo Imai, hypothesized that caspase-1 might control IL-33 release from keratinocytes in vivo. Their reasoning drew on a parallel case: IL-1α, like IL-33, is a nuclear cytokine stored under steady-state conditions, and its extracellular release requires caspase-1. Previous studies, however, had suggested that IL-33 release is independent of caspase-1, but those conclusions came largely from non-cutaneous tissues or in vitro systems. In the airway epithelium, for example, allergen protease-activated stress granule assembly and gasdermin D fragmentation have been shown to control IL-33 secretion without caspase-1. The Japanese team suspected that the skin might operate by different rules, and their new findings support that idea.

The first technical step was to establish where caspase-1 actually resides in skin. Using immunofluorescence staining of mouse skin sections with a Cy3-conjugated anti-caspase-1 P10 polyclonal antibody, the researchers detected caspase-1 immunoreactivity in the nuclei of epidermal keratinocytes. No specific staining appeared in caspase-1/11-deficient mice, which served as negative controls. This was a significant observation because earlier studies had concluded that caspase-1 expression was restricted to hematopoietic cells, conclusions based largely on the absence of detectable interleukin-1 beta-processing activity and the limited sensitivity of the detection methods available at the time. Subsequent work with improved methodologies has revealed low-level but functional caspase-1 expression in epithelial cells, including keratinocytes. For caspase-1 to be involved in the release of a nuclear alarmin like IL-33, the protease would need to be present in keratinocyte nuclei, and the new staining data confirm exactly that.

Next, the team examined what happens to nuclear IL-33 when the skin is stimulated. They applied 20 microliters of 0.5 percent 2,4-dinitrofluorobenzene (DNFB), a contact-sensitizing hapten dissolved in acetone and olive oil, to the left ear of mice while the right ear received vehicle alone. Six hours later, they processed the ear skin for immunofluorescence staining for IL-33, using an affinity-purified rabbit anti-mouse IL-33 polyclonal antibody detected with a biotinylated goat anti-rabbit IgG secondary antibody and streptavidin-conjugated Alexa Fluor 594, with nuclei counterstained using DAPI. The disappearance of nuclear IL-33 staining in keratinocytes was interpreted as evidence that IL-33 had been released into the extracellular space, an established surrogate readout that parallels findings in experimental allergic rhinitis, where allergen challenge induces a rapid loss of IL-33 staining in nasal epithelial cells alongside increased IL-33 levels in nasal lavage fluids.

The result was striking. In wild-type mice, IL-33 fluorescence in the epidermis was substantially reduced six hours after DNFB treatment, consistent with the team’s previous report that cutaneous stimulation triggers extracellular IL-33 release in vivo. In caspase-1/11-deficient mice, however, IL-33 immunoreactivity remained clearly detectable in the nuclei of epidermal keratinocytes at the same time point. In other words, deleting caspase-1/11 prevented the DNFB-induced loss of keratinocyte IL-33. Notably, quantitative real-time PCR showed that DNFB application increased Il33 mRNA expression in both wild-type and caspase-1/11-deficient mice, even though nuclear IL-33 staining persisted in the knockout animals. This indicates that Il33 transcription is induced by DNFB independently of IL-33 release, meaning the protease is specifically required for the release step rather than for the transcriptional response.

To test whether this release mechanism matters for actual disease, the researchers crossed their caspase-1/11-deficient mice with the hK14mIL33tg transgenic line, which overexpresses murine IL-33 in keratinocytes under the control of the human keratin-14 promoter. These IL33tg mice spontaneously develop atopic dermatitis-like skin inflammation. When caspase-1/11 was deleted in this background, the resulting IL33tg Casp1/11KO mice exhibited markedly attenuated skin inflammation compared with IL33tg mice. Histological examination of hematoxylin and eosin-stained skin sections showed pronounced leukocyte and eosinophil infiltration accompanied by epidermal hyperplasia in IL33tg mice, while these pathological features were minimal in the double-deficient animals, indicating a substantially reduced inflammatory response in the absence of caspase-1/11.

The molecular signature of the type 2 immune response told the same story. Quantitative PCR analysis of skin tissue, performed with a TaqMan RNA-to-Ct Kit and an ABI7900HT sequence detection system, revealed significant reductions in the expression of type 2 cytokines including Il4, Il5, and Il13, as well as Prg2, which encodes eosinophil peroxidase and serves as a specific marker of murine eosinophils. The reduction in Prg2 expression was consistent with the histological findings showing markedly reduced eosinophil infiltration in IL33tg Casp1/11KO mice. Together, these data indicate that caspase-1/11 deficiency suppresses IL-33-driven type 2 immune responses in the skin, dampening the entire downstream allergic cascade that IL-33 normally sets in motion through ILC2 activation.

The findings carry important caveats that the authors address candidly. The knockout mice used in the study have historically been described as caspase-1-deficient, but they are now recognized to carry a combined deficiency of both caspase-1 and caspase-11, because the Casp1 and Casp11 genes lie in close genomic proximity within the same gene cluster, resulting in simultaneous disruption of both loci in this strain. The potential contribution of caspase-11 therefore cannot be formally excluded. However, previous studies indicate that epithelial inflammasome-related responses, including IL-33 regulation, are mainly mediated by caspase-1 rather than caspase-11. Caspase-11 is primarily implicated in noncanonical inflammasome signaling in myeloid cells and localizes predominantly in the cytoplasm, making its direct involvement in the nuclear export of IL-33 from keratinocytes less likely. The authors also note that loss of nuclear staining does not directly quantify extracellular IL-33 levels, so future studies using biochemical measurements will be needed to confirm the release mechanism.

There is another puzzle worth noting. Several studies have suggested a role for caspase-1 in IL-33 inactivation rather than release, since IL-33 can be inactivated after maturation by caspase-1. If caspase-1-mediated inactivation were essential in vivo, IL-33-transgenic mice lacking caspase-1/11 would be expected to show exacerbated skin inflammation, yet the opposite was observed. The authors also point out that pharmacological inhibition of caspase-1 may not fully reflect its role in alarmin release, because for IL-1α the presence of caspase-1 protein, rather than its enzymatic activity, can be required for secretion. Because caspase-1/11 was deleted in all cells in the mice used, the possibility that caspase-1 deficiency in immune cells influences IL-33-induced skin inflammation cannot be excluded, though the marked reduction in inflammation suggests that caspase-1/11 deficiency affects an early step in IL-33-driven skin inflammation, most likely IL-33 release from keratinocytes.

The broader implication is that alarmin biology may be tissue-specific in ways the field has not fully appreciated. IL-33 can be released independently of caspase-1 in other tissues, notably the airway epithelium, where gasdermin D-mediated pathways dominate. But in the skin, the new evidence suggests that caspase-1 is involved in the pathogenic release of IL-33 from keratinocytes in vivo, and that this release step is a critical control point for atopic dermatitis-like inflammation. If the findings hold up in biochemical assays and in human tissue, they could reshape how researchers think about targeting IL-33 in atopic dermatitis, pointing to the release machinery within keratinocytes as a potential therapeutic frontier alongside the IL-33-blocking antibodies already in clinical development.

Subject of Research: Immunology

Article Title: Deficiency of inflammatory caspases attenuates IL-33–mediated dermatitis

Article References: Amaki, M., Murata, T., Kanazawa, N., & Imai, Y. (2026). Deficiency of inflammatory caspases attenuates IL-33–mediated dermatitis. Journal of Cutaneous Immunology and Allergy, 9, Article 16358. https://doi.org/10.3389/jcia.2026.16358

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.16358

Keywords: atopic dermatitis, IL-33, caspase-1, keratinocytes, alarmin, skin inflammation, type 2 cytokines, innate lymphoid cells, Deficiency, inflammatory, caspases, attenuates

The findings matter because schizophrenia has long been viewed primarily through the lens of dopamine signaling and abnormal brain development. Yet a growing body of evidence implicates chronic low-grade inflammation as a contributing factor, and immune signaling pathways have emerged as promising targets for understanding — and perhaps eventually treating — aspects of the illness that antipsychotic medications leave untouched. The IL-33/sST2 axis sits at a particularly interesting junction within that landscape, because it connects immune alarm signaling directly to both neural tissue and metabolic regulation.

IL-33 itself is a fascinating molecule. Often described as an “alarmin,” it is normally stored inside the nuclei of endothelial cells, epithelial cells and other structural tissues, and it is released when cells are damaged or stressed. Once outside the cell, IL-33 acts as a damage-associated molecular pattern — a DAMP in immunological shorthand — alerting the immune system to tissue injury. It exerts its effects by binding to a receptor called suppression of tumorigenicity-2, or ST2, which sits on the surface of immune cells, mast cells, and even neurons and glia. The brain is richly endowed with IL-33 and ST2 expression, particularly in astrocytes and microglia, the resident immune cells of the central nervous system, which has fueled speculation that dysregulated IL-33 signaling could contribute to the neuroinflammatory component of psychiatric disease.

There is a twist in the receptor biology that makes measuring this system tricky. The ST2 gene produces two major isoforms: a membrane-bound form that transmits signals into the cell, and a soluble decoy form, sST2, that floats freely in the blood and mops up IL-33 before it can bind its functional receptor. In other words, sST2 acts as a natural brake on IL-33 activity. When researchers measure both molecules in serum, the ratio between them offers a rough gauge of the balance between immune alarm signaling and its suppression. The new study examined exactly this balance in 39 patients with schizophrenia, 24 of their healthy siblings, and 25 unrelated healthy controls — a design that allows investigators to ask whether immune alterations are tied to the illness itself or to shared genetic and familial vulnerability.

Serum concentrations of IL-33 and sST2 were quantified using enzyme-linked immunosorbent assay, the workhorse technique of protein biomarker research, alongside a battery of metabolic measurements including waist circumference, blood pressure, fasting glucose, and lipid profiles. Cognitive performance was assessed using well-validated neuropsychological instruments, notably the Trail Making Test, which probes executive function and processing speed, while social and occupational functioning was rated with the Personal and Social Performance Scale. Symptom severity was measured with the Positive and Negative Syndrome Scale, and metabolic syndrome was defined by standard clinical criteria.

The headline result is a clear immune signature: patients with schizophrenia showed elevated IL-33 and reduced sST2 relative to healthy controls, a pattern consistent with heightened and insufficiently counteracted alarmin signaling. Intriguingly, the healthy siblings of patients — who share roughly half their genes with their ill relatives but do not have the diagnosis — showed IL-33 levels similar to controls rather than to patients. That pattern suggests the IL-33 elevation may be more closely tied to the illness state or its treatment than to inherited familial risk alone, though the authors are careful to note that the sibling subgroup was small and the result should be interpreted with caution. sST2 levels in siblings did not differ significantly from either the patient or control groups.

When the team explored how these immune markers relate to the clinical realities of schizophrenia, the picture became more nuanced. The IL-33/sST2 axis was associated with metabolic syndrome, the dangerous cluster of abdominal obesity, hypertension, dyslipidemia and insulin resistance that affects a large proportion of people with schizophrenia and dramatically shortens their life expectancy through cardiovascular disease. The markers also correlated with social functioning, the capacity to maintain relationships, work, and independent daily life that most strongly predicts long-term quality of life in this population. But when it came to the cognitive domain, the story changed: neither IL-33, nor sST2, nor their ratio showed significant correlations with executive function or processing speed, and metabolic parameters likewise showed no association with neurocognitive test performance.

This dissociation is scientifically telling. Cognitive impairments in schizophrenia are considered core features of the illness, tightly linked to neurodevelopment, and often present before the onset of psychosis. If the IL-33/sST2 axis tracks metabolic and functional outcomes but not cognition, it may be marking a distinct pathological pathway — one involving peripheral inflammation and metabolic dysregulation — rather than the neurodevelopmental processes that drive cognitive deficits. That distinction could matter enormously for future therapeutic strategies. Anti-inflammatory or immunomodulatory interventions might, for example, improve metabolic health and social outcomes in schizophrenia without being expected to rescue cognitive performance, and biomarkers like sST2 could eventually help identify which patients would benefit most.

The researchers also used receiver operating characteristic analysis to explore whether IL-33 or sST2 could serve as diagnostic cut-offs capable of distinguishing patients from controls. While the analysis yielded cut-off values with measurable discriminatory power, the authors are explicit that these findings do not support clinical use. The study is cross-sectional, meaning it captures a single moment in time and cannot establish whether immune changes precede or follow the illness and its treatments. The sample is small, particularly the sibling group, and the authors acknowledge in their conclusions that the exploratory nature of the work, the limited cohort size, and the absence of longitudinal data mean IL-33 and sST2 cannot yet be considered diagnostic or prognostic biomarkers for schizophrenia.

Those caveats are standard scientific humility, but they do not erase the study’s contribution. Replicated elevations of IL-33 with compensatory failure of its soluble decoy receptor would strengthen the case that alarmin signaling is a genuine player in schizophrenia biology, connecting the immune system, adipose tissue, and the social difficulties that define real-world disability in the disorder. Larger prospective cohorts, ideally following patients from illness onset and including first-episode and drug-naive participants to disentangle medication effects, are the necessary next step. For now, the study adds an intriguing new thread to the growing tapestry of psycho-immunology: the alarm signals of a stressed immune system may echo far beyond inflammation, shaping metabolism and the fabric of social life in people living with schizophrenia.

Subject of Research: The association of serum IL-33 and sST2 immune markers with metabolic syndrome, social functioning, and cognition in schizophrenia.

Article Title: IL-33/sST2 axis is associated with metabolic syndrome and social functioning, but not executive function or processing speed, in schizophrenia

Article References: Kaya, A. G., Ekinci, R. N., Çakmak, I. B., Uzdoğan, E. A., Almaz, A. B., & Göka, E. (2026). IL-33/sST2 axis is associated with metabolic syndrome and social functioning, but not executive function or processing speed, in schizophrenia. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08414-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08414-1

Keywords: schizophrenia, IL-33, sST2, inflammation, biomarkers, metabolic syndrome, social functioning, executive function, processing speed, immune system, psychiatry, alarmins